이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Development and Evaluation of a Parent-led Intervention Module for Early Autism Spectrum Disorder (PRIME-ASD) in Odisha, India: Protocol for a Multiphase Mixed-methods Study Including an Open-label Randomised Controlled Trial

2026년 9월 29일 업데이트: Dr. Debadatta Mohapatra, All India Institute of Medical Sciences, Bhubaneswar

Many families of young children with autism in India wait a long time for a diagnosis and specialist therapy, and receive little structured guidance on how to help their child at home. PRIME-ASD is a 12-week programme in which a trained therapist coaches parents or other main caregivers to use simple, play-based activities within everyday household and cultural routines to support their child's social interaction, communication, emotions, behaviour, sensory responses and thinking skills.

This study will test whether PRIME-ASD, added to usual care, reduces autism symptoms more than usual care alone. A total of 188 children aged 2-9 years with autism attending AIIMS Bhubaneswar, Odisha, India, will be randomly assigned in equal numbers to receive PRIME-ASD plus usual care or usual care alone. Autism symptoms will be measured with the Indian Scale for Assessment of Autism (ISAA) by assessors who do not know which group the child is in. The main comparison is at 12 weeks; the study will also look at behaviour, social maturity, whether any benefit lasts to 24 weeks, whether families can take part and find the programme acceptable, and safety. Some caregivers will be interviewed about their experience of delivering the programme at home.

연구 개요

상세 설명

Background. Parent-mediated interventions improve parent-child interaction and show smaller but consistent benefits for child social communication. Existing Indian adaptations were developed in other linguistic and service contexts and have not been co-designed with Odia-speaking families or aligned with the District Early Intervention Centres (DEIC) through which Odisha delivers early developmental services.

Development. PRIME-ASD was developed in earlier phases of a multiphase mixed-methods study: a systematic review and meta-analysis of randomised trials of parent-mediated interventions (registered with PROSPERO); in-depth interviews and focus groups with caregivers, providers and administrators; and a modified Delphi process (8-12 experts; consensus ≥80%) with content validation (I-CVI ≥0.78; S-CVI/Ave ≥0.80), face validation with 6-8 parents and field testing with 3-5 parent-child dyads. This record covers only the randomised controlled trial.

Design. Two-arm, parallel-group, open-label, assessor-blinded, superiority randomised controlled trial with 1:1 allocation and an embedded qualitative study, reported according to SPIRIT 2013 and CONSORT. Allocation uses a computer-generated sequence of randomly permuted blocks of variable size [2, 4 and 6], prepared by an independent statistician and concealed in sequentially numbered, opaque, sealed envelopes opened after the baseline assessment.

Intervention. PRIME-ASD comprises 12 weekly individual coaching sessions of about [60] minutes (didactic coaching, demonstration, coached caregiver-child practice with feedback and home-goal setting), weekly telephone follow-up of about [15-20] minutes and daily home practice of about [20-30] minutes across six domains aligned with the ISAA. Sessions are delivered in person at AIIMS Bhubaneswar, with synchronous video sessions when travel is not possible. Fidelity is monitored with attendance logs, home-practice checklists, an interventionist fidelity checklist and supervisor rating of [20%] of audio-recorded sessions.

Comparator. Treatment as usual (TAU): routine outpatient psychiatric review, psychoeducation and counselling, medication where clinically indicated and referral to available therapy services. TAU is not restricted in either arm, and co-interventions are recorded at each assessment.

Sample size. Assuming a standardised mean difference of 0.45 in ISAA score, two-sided α = 0.05 and 80% power, 79 children per arm are required; allowing for 15% attrition by 24 weeks, 94 per arm (188 in total) will be recruited.

Analysis. Intention to treat. The 12-week ISAA total score will be compared with analysis of covariance adjusted for baseline score [and any stratification factors]. Secondary outcomes will be analysed with linear mixed-effects models (arm, time, arm-by-time and baseline score) and logistic regression for response, without adjustment for multiplicity. Missing data will be handled by multiple imputation by chained equations, with complete-case, per-protocol and tipping-point sensitivity analyses. No interim efficacy analysis is planned.

Embedded qualitative study. After the 12-week assessment, approximately [15-20] intervention-arm caregivers, sampled on adherence and ISAA change, and the interventionists will be interviewed; findings will be merged with trial results in joint displays.

연구 유형

중재적

등록 (추정된)

188

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

2년 (어린이)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Child aged 2-9 years Diagnosis of autism spectrum disorder according to ICD-11 criteria, made by a psychiatrist after clinical evaluation and supported by the INCLEN Diagnostic Tool for ASD [or ISAA - TO CONFIRM] A primary caregiver (biological parent, legal guardian or family member responsible for most daily care) aged 18 years or older who is willing and able to attend coaching sessions, take part in telephone follow-up and practise activities at home for 12 weeks Access to a mobile telephone Written informed consent from the caregiver or legally authorised representative

Exclusion Criteria:

  • Severe or profound intellectual disability [threshold and instrument] Uncontrolled epilepsy or another medical condition that precludes participation Uncorrected severe visual or hearing impairment Caregiver with a severe mental illness or other condition that would prevent delivery of the module Current enrolment in another structured parent-training programme Plans to leave the catchment area within 6 months

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: PRIME-ASD plus treatment as usual - Experimental

Children and their primary caregivers receive the 12-week PRIME-ASD parent-led intervention in addition to treatment as usual.

Twelve weekly individual coaching sessions of about [60] minutes with a caregiver-child dyad, delivered by a [clinical psychologist / trained research therapist] in person at AIIMS Bhubaneswar or by synchronous video. Each session includes brief didactic coaching, live or video demonstration, coached caregiver-child practice with feedback and collaborative home-goal setting. Caregivers practise play-based routines at home for about [20-30] minutes daily across six domains (social relationship and reciprocity; emotional responsiveness; speech, language and communication; behaviour patterns; sensory aspects; cognitive component) and receive a weekly telephone follow-up of about [15-20] minutes. Materials include an Odia-language manual, parent handouts, daily activity checklists and demonstration videos.

활성 비교기: Behavioral: PRIME-ASD; Other: Treatment as usual

Children continue treatment as usual alone, without restriction.

Children continue treatment as usual alone, without restriction.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change in autism symptom severity (ISAA total score) at 12 weeks
기간: Baseline and 12 weeks

Indian Scale for Assessment of Autism (ISAA) total score, rated by a masked clinician. 40 items scored 1-5; total 40-200; higher scores indicate greater severity (lower is better). Between-arm adjusted mean difference with 95% CI, analysis of covariance adjusted for baseline score.

Baseline and 12 weeks

2차 결과 측정

결과 측정
측정값 설명
기간
Maintenance of change in ISAA total score
기간: Baseline and 24 weeks

ISAA total score (40-200; higher scores indicate greater severity), masked clinician rating; adjusted mean difference from a linear mixed-effects model.

Baseline and 24 weeks
Change in ISAA domain scores
기간: Baseline, 12 weeks and 24 weeks

Scores on the six ISAA domains (social relationship and reciprocity; emotional responsiveness; speech, language and communication; behaviour patterns; sensory aspects; cognitive component); higher scores indicate greater severity

Baseline, 12 weeks and 24 weeks
Change in behavioural symptoms (Aberrant Behavior Checklist-Community)
기간: Baseline, 12 weeks and 24 weeks

Caregiver-rated ABC-C total and five subscale scores (irritability; social withdrawal; stereotypic behaviour; hyperactivity/non-compliance; inappropriate speech); 58 items; higher scores indicate more problem behaviour.

Baseline, 12 weeks and 24 weeks
Proportion of responders
기간: 12 weeks and 24 weeks

Percentage of children with an ISAA reduction of at least 0.5 SD of the baseline score and, separately, a VSMS gain of at least 0.3 SD; adjusted odds ratio with 95% CI.

12 weeks and 24 weeks
Feasibility of the intervention
기간: Enrolment to 24 weeks

Recruitment rate, retention, session attendance, home-practice adherence and intervention fidelity, reported as proportions with 95% CI or median (IQR).

Enrolment to 24 weeks
Acceptability of the intervention
기간: 12 weeks

Caregiver-rated Acceptability of Intervention Measure, Intervention Appropriateness Measure and Feasibility of Intervention Measure (each scored 1-5; higher scores indicate greater acceptability, appropriateness or feasibility).

12 weeks
Number of participants with adverse events and serious adverse events
기간: Baseline to 24 weeks

Adverse events and serious adverse events by arm, severity and relatedness, from caregiver report and clinician review.

Baseline to 24 weeks

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2027년 1월 15일

기본 완료 (추정된)

2027년 12월 14일

연구 완료 (추정된)

2027년 12월 15일

연구 등록 날짜

최초 제출

2026년 9월 29일

QC 기준을 충족하는 최초 제출

2026년 9월 29일

처음 게시됨 (실제)

2026년 10월 5일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 10월 5일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 29일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

미정

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다